Reports related to this article:
Project(s): View 5 related projects in PECWeb
Plant(s): View 3 related plants in PECWeb
en
Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--In no small part thanks to Uncle Sam, the U.S. Mid-Atlantic region has 163 active life science projects representing a whopping $8 billion in capital investment. Out of that total, 115 have future kick-off dates and carry a total investment value (TIV) of $3.5 billion. A number of the corporate-sourced construction projects received a healthy share of funding courtesy of the U.S. government.
Click on the image at right for a graph detailing active projects by state.
A case in point regarding the duality of funding for many of these projects is Novartis AG's (NYSE:NVS) $1 billion, 163-acre vaccine manufacturing and research campus (500,000 square feet of manufacturing, laboratory and office space) in Holly Springs, North Carolina. Formally known as the United States Flu Cell Culture Facility (USFCC), the site produces seasonal flu cell-culture vaccines and pre-pandemic vaccines, and has the capacity to manufacture 150 million doses of pandemic vaccine within six months of an influenza pandemic declaration. The actual construction and engineering technology for the Holly Springs plant were partially funded through contracts issued by the U.S. Department of Health and Human Services (HHS).
Click here to gain instant access to the all-new 2014 North American Pharmaceutical-Biotech Outlook.
Next up for the Holly Springs site are three additional projects totaling $130 million, including injectable flu vaccine filling lines, a research and development laboratory, and a warehouse. In addition to these specific projects, Novartis traditionally spends more than $15 million annually for various capital upgrades at the site.
Another recipient of a federal research grant under the HHS' $220 million program to create three flu vaccine production facilities in the U.S. is Emergent BioSolutions Incorporated (NYSE:EBS) (Rockville, Maryland). The company is planning a $50 million expansion of its anthrax and flu vaccine production and research & development facility in Baltimore.
After signing a $21 million Technology Investment Agreement with the federal Defense Advanced Research Projects Agency (DARPA) to develop a scaled-up process capable of producing substantial doses of immunogenic, pandemic vaccine in a brief amount of time, Medicago USA, a subsidiary of Medicago Incorporated (Quebec City, Quebec), constructed a 97,000-square-foot plant in Research Triangle Park (RTP), North Carolina. On an annual basis, the facility could have a production capacity of up to 30 million doses of quadrivalent seasonal influenza vaccine, or 120 million doses of pandemic influenza vaccine. Medicago now has a $4 million project planned for the site to expand and upgrade its water-for-injection (WIF)/purified water systems. The company also is planning $1 million in general plant upgrades.
View Plant Profile - 3010398 1067716 1058309
View Project Report - 300151887 300138240 300138257 300138440 300147134
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, three offices in North America and 10 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities.
Click on the image at right for a graph detailing active projects by state.A case in point regarding the duality of funding for many of these projects is Novartis AG's (NYSE:NVS) $1 billion, 163-acre vaccine manufacturing and research campus (500,000 square feet of manufacturing, laboratory and office space) in Holly Springs, North Carolina. Formally known as the United States Flu Cell Culture Facility (USFCC), the site produces seasonal flu cell-culture vaccines and pre-pandemic vaccines, and has the capacity to manufacture 150 million doses of pandemic vaccine within six months of an influenza pandemic declaration. The actual construction and engineering technology for the Holly Springs plant were partially funded through contracts issued by the U.S. Department of Health and Human Services (HHS).
Click here to gain instant access to the all-new 2014 North American Pharmaceutical-Biotech Outlook.
Next up for the Holly Springs site are three additional projects totaling $130 million, including injectable flu vaccine filling lines, a research and development laboratory, and a warehouse. In addition to these specific projects, Novartis traditionally spends more than $15 million annually for various capital upgrades at the site.
Another recipient of a federal research grant under the HHS' $220 million program to create three flu vaccine production facilities in the U.S. is Emergent BioSolutions Incorporated (NYSE:EBS) (Rockville, Maryland). The company is planning a $50 million expansion of its anthrax and flu vaccine production and research & development facility in Baltimore.
After signing a $21 million Technology Investment Agreement with the federal Defense Advanced Research Projects Agency (DARPA) to develop a scaled-up process capable of producing substantial doses of immunogenic, pandemic vaccine in a brief amount of time, Medicago USA, a subsidiary of Medicago Incorporated (Quebec City, Quebec), constructed a 97,000-square-foot plant in Research Triangle Park (RTP), North Carolina. On an annual basis, the facility could have a production capacity of up to 30 million doses of quadrivalent seasonal influenza vaccine, or 120 million doses of pandemic influenza vaccine. Medicago now has a $4 million project planned for the site to expand and upgrade its water-for-injection (WIF)/purified water systems. The company also is planning $1 million in general plant upgrades.
View Plant Profile - 3010398 1067716 1058309
View Project Report - 300151887 300138240 300138257 300138440 300147134
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, three offices in North America and 10 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities.
